Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ALKS 5461 in Major Depressive Disorder
NCT01381107Phase 2Completed
- Sponsor
- Alkermes
- Start
- May 2011
- Primary completion
- Jul 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine, samidorphan in major depressive disorder (MDD), sponsored by Alkermes. Started May 2011; status: completed.
02
Drugs
buprenorphinesamidorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01381107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381107.